...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Zenith Epigentics and Resverlogix update 22 Jan 2018

Thanks for sharing Tada, good commentary. Your statement at the end regarding double blinded trials and investor fatigue is very true. Would have been nice if management could have gotten around to timely commencement of other trials to at least somewhat offset this. I really think if they could get some of these trials underway that it might give some of those watching on the sidelines a reason to jump in. Long ago Don was telling us that these are much smaller and much cheaper trials and that they would serve as “inflection points” for RVX stock along the road to completion of BETOnMACE. IMO being unable to progress with these trials leaves RVX looking very much like a one trick pony with inept management that is seemingly capable of producing little more than hot air. 

Share
New Message
Please login to post a reply